About ImmunoBiochem and Pipeline
ImmunoBiochem is developing novel degrader-antibody conjugate (DAC) therapeutics that unlock unique mechanisms of action and enable unprecedented precision in immunology and inflammation. Leveraging modern computational tools and biological models, ImmunoBiochem is redefining antibody conjugates by combining the robustness of ADCs with the catalytic power of targeted protein degraders, unlocking new opportunities to modulate disease pathways not accessible to other modalities.
